Clinical metal artifact reduction sequence (MARS) magnetic resonance imaging (MRI) protocols at 3 Tesla (3T) on hip arthroplasty implants pose minimal risk of thermal injury, according to a recent study. The findings were presented at the American Roentgen Ray Society (ARRS) 2019 Annual Meeting, May 5-10 in Honolulu.

Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (NPs) using multimodal positron emission tomography/magnetic resonance imaging (PET/MRI) offers promising improvements in imaging capabilities. The paper is published in the American Chemical Society journal ACS Omega.

ControlRad Inc. announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its ControlRad Trace and the company has initiated its commercial launch. The ControlRad Trace is the only technology, according to the company, that can be integrated into existing mobile C-arms to reduce radiation in any fluoroscopic imaging procedure.

Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of experiencing side-effects from their radiation therapy, while cure rates are almost identical between the two groups. Researchers in the Perelman School of Medicine at the University of Pennsylvania conducted the largest review of its kind to evaluate whether or not patients undergoing radiation therapy at the same time as chemotherapy experienced serious adverse events within 90 days. They will present their findings at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago (Abstract #6521).

Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast Cancer Risk Evaluation Tool improves breast cancer risk stratification. The research suggests VolparaDensity could be used to help guide personalized medicine through risk-adapted screening.

Santa Casa de Misericordia has selected Carestream to replace its legacy diagnostic workflow technology across all seven of its hospitals in Porto Alegre, the capital and largest city of the Brazilian state of Rio Grande do Sul.

Philips announced that Philips Lumify, a point-of-care ultrasound device, has earned the U.S. Army Airworthiness Certification after passing a series of rigorous military tests. This certification now allows Philips Lumify to be added to an Army medic’s bag in a helicopter so they can immediately evaluate if a solider has a life-threatening injury, such as internal bleeding, a broken rib or a bullet wound to critical organs. The Airworthiness Certification also allows medics using Philips Lumify to facilitate continuity of care between the battlefield, aircraft, ambulance and emergency room.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new research and technology innovations they are using. So, it was an honor when ITN was invited to conduct a site visit at Henry Ford last fall to tour the hospital's facilities and conduct numerous video interviews to better understand the workings of the institution. 
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now